Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARM210 in CPVT1
NCT05122975Phase 2Terminated
- Sponsor
- RyCarma Therapeutics
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in catecholaminergic polymorphic ventricular tachycardia (CPVT) comparing S48168 (ARM210) with Matching Placebo (2 arms). Primary endpoint: Change in ectopy score from baseline to Day 28. Started Aug 2023; status: terminated.
02
Drugs
Surlorian
03
Conditions
catecholaminergic polymorphic ventricular tachycardia (CPVT)
Beyond the preview
Go deeper on NCT05122975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05122975.